title: Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C.
abstract: OBJECTIVE
  We estimated HCV reinfection rate and its associated risk factors in inmates with chronic hepatitis C who had achieved sustained virological response (SVR) after completing combination therapy while in prison.
  
  
  METHODS
  Individuals who had achieved an SVR after treatment provided from January 2003 to December 2009 at four prisons in Catalonia, had been tested annually for HCV RNA and were in prison during 2010, were invited to complete a questionnaire regarding risk factors for reinfection. Incidence rate was calculated as 100 person-years of follow-up. Risk factors potentially associated with reinfection were evaluated by bivariate log-rank test and multivariate Cox regression analysis.
  
  
  RESULTS
  One hundred and nineteen subjects who had achieved an SVR agreed to participate. 98% were male, with a median age of 33.3 ± 6.3 years and 81% had a history of injection drug use (IDU). After a mean follow-up of 1.4 years, HCV reinfection was identified in nine former IDUs, seven with HCV genotype switch, for an overall reinfection rate of 5.27 cases per 100 person-years. Reinfection incidence was significantly higher among active drug users (HR=12.47; 95% CI: 2.90-53.71), HIV co-infected (HR=9.95; 95% CI: 1.73-57.34), and those engaging in more than one risk behaviors after treatment (HR=7.47; 95% CI: 1.19-46.89).
  
  
  CONCLUSIONS
  HCV reinfection among inmates after successful treatment is high especially in those with ongoing IDU. Preventative interventions at diagnosis and during and after HCV treatment should be strongly reinforced.
authors.affiliation: Health Services of Barcelona Men's Penitentiary Centre, Barcelona, Spain. andres.marco.m@gmail.com
authors.forename: A
authors.initials: A
authors.lastname: Marco
authors.forename: J I
authors.initials: JI
authors.lastname: Esteban
authors.forename: C
authors.initials: C
authors.lastname: Solé
authors.forename: A
authors.initials: A
authors.lastname: da Silva
authors.forename: J
authors.initials: J
authors.lastname: Ortiz
authors.forename: M
authors.initials: M
authors.lastname: Roget
authors.forename: C
authors.initials: C
authors.lastname: Sarriera
authors.forename: N
authors.initials: N
authors.lastname: Teixidó
authors.forename: R A
authors.initials: RA
authors.lastname: Guerrero
authors.forename: J A
authors.initials: JA
authors.lastname: Caylà
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000453:epidemiology / Q000635:transmission*; D006801:Humans; D015994:Incidence; D008297:Male; D011329:Prisoners; D012367:RNA, Viral / Q000097:blood; D012008:Recurrence; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D015819:Substance Abuse, Intravenous / Q000150:complications; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral